Overview
Compare with TAYLOR DEVICES, INC., Ouster or Hongli Group Inc., or pick any stock.
- TickerCHRN on Nasdaq1
- IndustryGeneral Industrial Machinery & Equipment, NEC1
- HeadquartersDallas, Texas1
- Incorporated inNV3
- Business address3811 Turtle Creek Blvd., Suite 2100, Dallas, Tx 752193
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
On May 5, 2026, we consummated the previously announced business combination transaction (the “Business Combination”) contemplated by that certain Contribution and Exchange Agreement (the “Contribution and Exchange Agreement”), dated February 15, 2026, by and among Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso”), APLD Intermediate HoldCo LLC, a Delaware limited liability company (“APLD Intermediate”), APLD ChronoScale HoldCo LLC, a Delaware limited liability company and a wholly-owned subsidiary of APLD Intermediate (“Contributor”), each a wholly-owned direct or indirect subsidiary of Applied Digital Corporation, a Nevada corporation (“Applied Parent”), and Cloud, which immediately prior to the consummation of the Business Combination (the “Closing”) was a wholly-owned indirect subsidiary of Applied Parent and a direct subsidiary of Contributor. Upon the Closing, Ekso changed …5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
-52.4%Operating margin2
-70.3%Net margin2
459.4%Revenue growth, 20262
-28.0%Return on equity2
0.00×Debt to equity2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 58% of the revenue ChronoScale Holdings Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $9.7M | $7.4M |
| Other Country | $2.9M | $2.4M |
| Asia Pacific | $1.9M | $1.5M |
| France | $3.0M | $1.4M |
| Americas Other | $421.0K | $72.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue82¢$88.7M
- Selling, general and admin18¢$19.8M
Out of $71.6M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2026
- Kept or used elsewhere100¢$39.1M
Out of $39.1M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Total revenue | $71.6M | $84.4M |
| Cost of revenues | $88.7M | $115.3M |
| Selling, general and administrative | $19.8M | $24.8M |
| Loss (gain) on sale of assets | $598.0K | -$414.0K |
| Total costs and expenses | $109.1M | $139.7M |
| Operating loss | -$37.5M | -$55.3M |
| Interest expense, net | $9.6M | $17.4M |
| Loss on change in fair value of warrants | $2.2M | $0 |
| Other Expense, net | $8.0K | $0 |
| Net loss from continuing operations before income tax expense | -$49.3M | -$72.7M |
| Income tax expense (benefit) | $0 | $0 |
| Net loss from continuing operations | -$49.3M | -$72.7M |
| Net loss from discontinued operations | -$1.0M | $0 |
| Net loss | -$50.3M | -$72.7M |
| Continuing operations, basic (in dollars per share) | -$0 | -$1 |
| Continuing operations, diluted (in dollars per share) | -$0 | -$1 |
| Discontinued operations, basic (in dollars per share) | -$0 | $0 |
| Discontinued operations, diluted (in dollars per share) | -$0 | $0 |
| Basic net loss per share (in dollars per share) | -$0.36 | -$0.53 |
| Diluted net loss per share (in dollars per share) | -$0.36 | -$0.53 |
| Basic weighted average number of shares outstanding (in shares) | 138.7M shares | 138.2M shares |
| Diluted weighted average number of shares outstanding (in shares) | 138.7M shares | 138.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-05-31 | 2026-04-30 | 2025-05-31 | 2024-05-31 |
|---|---|---|---|---|
| Cash | $9.7M | $2.4M | ||
| Accounts receivable | $12.5M | $3.8M | ||
| Prepaid expenses and other current assets | $2.2M | $223.0K | ||
| Current assets held for sale | $19.8M | $0 | ||
| Total current assets | $44.2M | $6.4M | ||
| Property and equipment, net | $32.1M | $10.9M | ||
| Operating lease right of use assets, net | $72.0M | $91.4M | ||
| Finance lease right of use assets, net | $122.5M | $195.5M | ||
| Goodwill | $54.5M | $0 | ||
| Other assets | $520.0K | $0 | ||
| TOTAL ASSETS | $325.9M | $304.2M | ||
| Accounts payable | $9.1M | $4.0M | ||
| Accrued liabilities | $3.7M | $572.0K | ||
| Current portion of operating lease liability | $18.1M | $16.1M | ||
| Current portion of finance lease liability | $47.6M | $133.4M | ||
| Current portion of debt | $3.4M | $0 | ||
| Current deferred revenue | $0 | $3.6M | ||
| Current liabilities held for sale | $5.0M | $0 | ||
| Total current liabilities | $86.9M | $157.6M | ||
| Long-term portion of operating lease liability | $40.3M | $58.4M | ||
| Long-term portion of finance lease liability | $10.7M | $0 | ||
| Long-term debt | $474.0K | $12.0M | ||
| Warrants and rights outstanding | $5.5M | $0 | ||
| Total liabilities | $143.8M | $228.0M | ||
| Convertible preferred stock, $0.001 par value; 10,000 shares authorized; 3 issued and outstanding as of May 31, 2026, with a $2,926 redemption value; none outstanding as of May 31, 2025 | $2.0M | $3.9M | $0 | $0 |
| Common stock, $0.001 par value; 290,000 shares authorized; 145,212 and 138,217 shares issued and outstanding as of May 31, 2026 and May 31, 2025, respectively | $145.0K | $138.0K | ||
| Additional paid in capital | $379.3M | $225.2M | ||
| Accumulated deficit | -$199.5M | -$149.1M | ||
| Total stockholders equity | $180.0M | $76.2M | $148.9M | |
| TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY | $325.9M | $304.2M | ||
| Temporary equity, par or stated value per share (in dollars per share) | $0.00 | |||
| Temporary equity, shares authorized (in shares) | 10.0M shares | |||
| Temporary equity, shares issued (in shares) | 3.0K shares | |||
| Temporary equity, shares outstanding (in shares) | 2.9K shares | 0 shares | 0 shares | |
| Redemption value | $2.9M | $2.9M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 290.0M shares | 290.0M shares | ||
| Common stock, shares issued (in shares) | 145.2M shares | 138.2M shares | ||
| Common stock, shares outstanding (in shares) | 145.2M shares | 138.2M shares |
| Period ending | 2026-05-31 | 2026-04-30 | 2025-05-31 | 2024-05-31 |
|---|---|---|---|---|
| Cash | $9.7M | $2.4M | ||
| Accounts receivable | $12.5M | $3.8M | ||
| Prepaid expenses and other current assets | $2.2M | $223.0K | ||
| Current assets held for sale | $19.8M | $0 | ||
| Total current assets | $44.2M | $6.4M | ||
| Property and equipment, net | $32.1M | $10.9M | ||
| Operating lease right of use assets, net | $72.0M | $91.4M | ||
| Finance lease right of use assets, net | $122.5M | $195.5M | ||
| Goodwill | $54.5M | $0 | ||
| Other assets | $520.0K | $0 | ||
| TOTAL ASSETS | $325.9M | $304.2M | ||
| Accounts payable | $9.1M | $4.0M | ||
| Accrued liabilities | $3.7M | $572.0K | ||
| Current portion of operating lease liability | $18.1M | $16.1M | ||
| Current portion of finance lease liability | $47.6M | $133.4M | ||
| Current portion of debt | $3.4M | $0 | ||
| Current deferred revenue | $0 | $3.6M | ||
| Current liabilities held for sale | $5.0M | $0 | ||
| Total current liabilities | $86.9M | $157.6M | ||
| Long-term portion of operating lease liability | $40.3M | $58.4M | ||
| Long-term portion of finance lease liability | $10.7M | $0 | ||
| Long-term debt | $474.0K | $12.0M | ||
| Warrants and rights outstanding | $5.5M | $0 | ||
| Total liabilities | $143.8M | $228.0M | ||
| Convertible preferred stock, $0.001 par value; 10,000 shares authorized; 3 issued and outstanding as of May 31, 2026, with a $2,926 redemption value; none outstanding as of May 31, 2025 | $2.0M | $3.9M | $0 | $0 |
| Common stock, $0.001 par value; 290,000 shares authorized; 145,212 and 138,217 shares issued and outstanding as of May 31, 2026 and May 31, 2025, respectively | $145.0K | $138.0K | ||
| Additional paid in capital | $379.3M | $225.2M | ||
| Accumulated deficit | -$199.5M | -$149.1M | ||
| Total stockholders equity | $180.0M | $76.2M | $148.9M | |
| TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY | $325.9M | $304.2M | ||
| Temporary equity, par or stated value per share (in dollars per share) | $0.00 | |||
| Temporary equity, shares authorized (in shares) | 10.0M shares | |||
| Temporary equity, shares issued (in shares) | 3.0K shares | |||
| Temporary equity, shares outstanding (in shares) | 2.9K shares | 0 shares | 0 shares | |
| Redemption value | $2.9M | $2.9M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 290.0M shares | 290.0M shares | ||
| Common stock, shares issued (in shares) | 145.2M shares | 138.2M shares | ||
| Common stock, shares outstanding (in shares) | 145.2M shares | 138.2M shares |
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Net loss | -$50.3M | -$72.7M |
| Depreciation and amortization | $60.3M | $80.7M |
| Stock-based compensation | $1.3M | -$1.5M |
| Lease expense | $21.0M | $30.9M |
| Loss on change in fair value of warrants | $2.2M | $0 |
| Loss (gain) on sale of assets | $598.0K | -$414.0K |
| Accounts receivable | -$8.5M | -$3.8M |
| Prepaid expenses and other current assets | -$1.9M | $111.0K |
| Other assets | -$520.0K | $581.0K |
| Accounts payable | $4.6M | -$9.0M |
| Accrued liabilities and other noncurrent liabilities | -$453.0K | -$1.0M |
| Lease assets and liabilities | $14.4M | -$3.5M |
| Deferred revenues | -$3.7M | -$27.6M |
| CASH FLOW PROVIDED BY (USED IN) OPERATING ACTIVITIES | $39.1M | -$7.2M |
| Net cash acquired in reverse merger acquisition | $1.7M | $0 |
| Purchases of property and equipment and other assets | -$26.9M | -$1.4M |
| CASH FLOW USED IN INVESTING ACTIVITIES | -$25.2M | -$1.4M |
| Principal transfer of SAFE agreement to Applied Parent | -$12.0M | $0 |
| Repayment of finance leases | -$89.5M | -$114.7M |
| Proceeds from issuance of common stock | $15.8M | $0 |
| Common stock issuance costs | -$750.0K | $0 |
| Proceeds from issuance of SAFE agreement included in long-term debt | $0 | $12.0M |
| Capital contributions from Applied Parent | $75.4M | $113.7M |
| Proceeds from exercise of warrants | $4.5M | $0 |
| CASH FLOW (USED IN) PROVIDED BY FINANCING ACTIVITIES | -$6.6M | $11.0M |
| NET INCREASE IN CASH | $7.3M | $2.4M |
| Fair value of assets acquired resulting from reverse merger | $74.7M | $0 |
| 138,217 shares issued in recapitalization adjustment resulting from reverse merger | $57.6M | $0 |
| Fair value of liabilities assumed from reverse merger acquisition | $18.8M | $0 |
| Deemed dividend in connection with equity financings | $113.0K | $0 |
| Series B Preferred shares converted to common | $2.0M | $0 |
| Operating right-of-use assets obtained by lease obligation | $0 | $20.3M |
| Finance right-of-use assets obtained by lease obligation | $5.9M | $64.4M |
| Property and equipment in accounts payable and accrued liabilities | $0 | $1.4M |
| Modification of liability classified incentive award to equity classified award | $2.4M | $0 |
| Share issuance of restricted stock units | $1.0K | $0 |
| Interest paid | $9.5M | $17.3M |
| Shares of Applied Parent issued in exchange for reverse merger (in shares) | 138.2K shares |
No quarter-by-quarter statement was filed.
Corporate structure
ChronoScale Holdings Corp sits at the top of its group. 6 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ChronoScale Holdings Corp
- Applied Digital Corp. Filed SCHEDULE 13D/A on ChronoScale Holdings Corp, latest Jun 26, 2026 (2 filings since May 12, 2026)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on ChronoScale Holdings Corp, latest May 15, 2026 (6 filings since Nov 14, 2024)
- Mink Brook Asset Management LLC Filed SCHEDULE 13G/A on ChronoScale Holdings Corp, latest May 14, 2026 (2 filings since Apr 9, 2026)
- Keith Kosow Filed SCHEDULE 13G on ChronoScale Holdings Corp, latest Mar 19, 2026
- Daniel Asher Filed SCHEDULE 13G/A on ChronoScale Holdings Corp, latest Jan 29, 2026 (2 filings since Jan 8, 2026)
- Kent Lake PR LLC Filed SCHEDULE 13G/A on ChronoScale Holdings Corp, latest Feb 14, 2025 (2 filings since Sep 12, 2024)
- Azimut Investments S.A. Filed SC 13G/A on ChronoScale Holdings Corp, latest Feb 11, 2022
- ChronoScale Holdings Corp Dallas, Texas
- ChronoScale Corporation Subsidiary · Nevada, United States
- ChronoScale Intermediate LLC Subsidiary · Nevada, United States
- Ekso Bionics (Asia) Pte. Ltd. Subsidiary · Singapore
- Ekso Bionics GmbH Subsidiary · Germany
- SAI Computing LLC Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What ChronoScale Holdings Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $40.5M2 May 31, 2026 | $13.6M2 May 31, 2025 | +197.7% |
| Accumulated depreciation | $8.4M2 May 31, 2026 | $2.7M2 May 31, 2025 | +213.8% |
| Property and equipment, net | $32.1M2 May 31, 2026 | $10.9M2 May 31, 2025 | +193.7% |
| Finance-lease assets | $122.5M2 May 31, 2026 | $195.5M2 May 31, 2025 | −37.3% |
| Operating-lease assets (leased space) | $72.0M2 May 31, 2026 | $91.4M2 May 31, 2025 | −21.2% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $54.5M2 May 31, 2026 | $02 May 31, 2025 | |
| Intangible assets, net (excluding goodwill) | $3.5M6 Dec 31, 2025 | $4.6M6 Dec 31, 2024 | −23.6% |
| Accumulated amortization | $970.0K6 Dec 31, 2025 | $640.0K6 Dec 31, 2024 | +51.6% |
| Finite-lived intangibles, net | $1.8M6 Dec 31, 2025 | $2.3M11 Dec 31, 2024 | −22.5% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $4.8M6 Dec 31, 2025 | $4.6M6 Dec 31, 2024 | +5.5% |
| Raw materials | $3.6M6 Dec 31, 2025 | $3.6M6 Dec 31, 2024 | +1.2% |
| Work in process | $102.0K6 Dec 31, 2025 | $177.0K6 Dec 31, 2024 | −42.4% |
| Finished goods | $1.1M6 Dec 31, 2025 | $843.0K6 Dec 31, 2024 | +33.7% |
Properties, in its own words
Our principal executive office is currently located at 2440 Sand Hill Road, Suite 400, Menlo Park, California 94025, where we lease 4,503 square feet.
We lease 1.5 MW, 5 MW, and 7.5 MW of power capacity and space from third-party-owned colocation data centers in Minnesota, Utah, and Colorado, respectively. We use these locations as operating space.
Item 2 of the 10-K filed Aug 19, 2026.5
Leadership
Who has led ChronoScale Holdings Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerJack Peurach Aug 7, 2018 to Sep 2, 202116
- Chief executive officerTom Looby Mar 3, 2016 to Sep 12, 201717
- Chief executive officerNathan Harding May 6, 2015 to Jun 15, 201518
- PresidentJack Peurach Sep 2, 2021 to Sep 2, 202119
- PresidentRuss Angold May 6, 2015 to Mar 27, 201820
- PresidentTom Looby May 6, 2015 to Sep 12, 201721
- Chief financial officerJohn Glenn Aug 22, 2018 to Mar 28, 202222
- Chief financial officerMax Scheder-Bieschin May 6, 2015 to Jun 8, 201823
- Chief operating officerRuss Delonzor Jul 24, 2018 to Jul 24, 201824
Board members and other officers (25)
- Chief Technology OfficerRajasekar Jegannathan Jul 24, 2026 to now25
- VP of Sales, AmericasChristian Babini Nov 5, 2018 to Nov 5, 201826
- Vice Pres., Global MarketingGregory Davault Jan 19, 2017 to Mar 27, 201827
- Vice Pres., OperationsRuss Delonzor Jan 19, 2017 to Jun 8, 201828
- Board memberDouglas S. Miller May 15, 2026 to now29
- Board memberElla Gendel May 15, 2026 to now30
- Board memberRichard N. Nottenburg May 15, 2026 to now31
- Board memberWes Cummins May 15, 2026 to now32
- Board memberWilliam M. Clancy May 15, 2026 to now33
- Board memberAndrew Cordell Schaap Jun 30, 2026 to now34
- Board memberDeborah Lafer Scher Jun 14, 2024 to now35
- Board memberMary Ann Cloyd Jan 4, 2021 to now36
- Board memberCorinna Lathan Dec 28, 2021 to now37
- Board memberRhonda A. Wallen Dec 31, 2020 to Jun 27, 202338
- Board memberKecheng Li Mar 20, 2018 to now39
- Board memberThomas A. Schreck Nov 5, 2018 to Jul 27, 202040
- Board memberHoward D. Palefsky Mar 31, 2017 to Jul 7, 201741
- Board memberTheodore T. Wang Sep 25, 2017 to Nov 12, 202042
- Board memberTom Looby Sep 27, 2016 to Sep 12, 201743
- Board memberAmy McBride Wendell May 6, 2015 to Sep 15, 201744
- Board memberDaniel Boren May 6, 2015 to Sep 5, 201745
- Board memberJack Peurach May 6, 2015 to Sep 2, 202146
- Board memberMarilyn Hamilton May 6, 2015 to Jul 27, 202047
- Board memberNathan Harding May 6, 2015 to Jun 15, 201518
- Board memberStanley Stern May 6, 2015 to Dec 6, 202248
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ChronoScale Corporation Nevada4
- ChronoScale Holdings Corporation Nevada4
- ChronoScale Intermediate LLC Nevada4
- Ekso Bionics (Asia) Pte. Ltd. Singapore4
- Ekso Bionics GmbH Germany4
- Ekso Bionics, Inc. Delaware4
- SAI Computing LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 15, 20268-K Results of operations49
- Oct 6, 20268-K Executive or director change50
- Oct 2, 20268-K Executive or director change; Bylaws or fiscal year changed; Regulation FD disclosure51
- Sep 16, 20268-K Entered a material agreement52
- Aug 27, 20268-K Regulation FD disclosure; Other events53
- Aug 18, 20268-K Executive or director change54
- Jun 30, 20268-K Executive or director change; Other events55
- Jun 30, 20268-K Other events56
- Jun 26, 20268-K Entered a material agreement; New debt or obligation57
- Jun 4, 20268-K Exit or restructuring costs58
- May 20, 20268-K Executive or director change59
- May 5, 20268-K Entered a material agreement; Completed an acquisition or sale; Results of operations60
- Aug 7, 2018New chief executive Jack Peurach becomes CEO16
- Mar 3, 2016New chief executive Tom Looby becomes CEO17
- May 6, 2015New chief executive Nathan Harding becomes CEO18
Calendar
When it reported results
- Oct 15, 2026Reported quarterly or annual results49
- May 5, 2026Reported quarterly or annual results60
- Feb 17, 2026Reported quarterly or annual results61
- Oct 28, 2025Reported quarterly or annual results62
- Jul 28, 2025Reported quarterly or annual results63
- May 5, 2025Reported quarterly or annual results64
- Mar 3, 2025Reported quarterly or annual results65
- Jan 13, 2025Reported quarterly or annual results66
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
285 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 64 major events, 115 insider forms, 16 large holders, 68 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Oct 14, 202610-Q EDGAR
- Oct 9, 2026EFFECT EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 20268-K EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-3 EDGAR
- Oct 2, 20268-K EDGAR
- Sep 29, 2026DRS EDGAR
- Sep 25, 2026ARS EDGAR
The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
44 open-market trades by officers, directors and large owners since October 2021: 13 buys and 31 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Jones Jason CChief Operating Officer | Buy | 1,308 | $11.85 | $15.5K | Form 4 |
| Mar 16, 2026 | Wong JeromeChief Financial Officer | Buy | 1,308 | $11.85 | $15.5K | Form 4 |
| Feb 19, 2026 | ASHER DANIEL10% owner | Buy | 15,540 | $12.30 | $191.1K | Form 4 |
| Feb 19, 2026 | ASHER DANIEL10% owner | Buy | 1,200 | $9.60 | $11.5K | Form 4 |
| Feb 13, 2026 | ASHER DANIEL10% owner | Buy | 27,192 | $9.03 | $245.6K | Form 4 |
| Feb 12, 2026 | ASHER DANIEL10% owner | Buy | 39,032 | $9.57 | $373.7K | Form 4 |
| Feb 11, 2026 | ASHER DANIEL10% owner | Buy | 20,611 | $9.69 | $199.7K | Form 4 |
| Feb 10, 2026 | ASHER DANIEL10% owner | Buy | 10,200 | $9.92 | $101.2K | Form 4 |
| Feb 9, 2026 | ASHER DANIEL10% owner | Buy | 4,800 | $9.96 | $47.8K | Form 4 |
| Feb 6, 2026 | ASHER DANIEL10% owner | Buy | 194 | $9.86 | $1.9K | Form 4 |
| Jan 6, 2026 | Jones Jason CChief Operating Officer | Sale | 1,320 | $9.25 | $12.2K | Form 4 |
| Dec 9, 2025 | Jones Jason CChief Operating Officer | Sale | 270 | $4.70 | $1.3K | Form 4 |
| Dec 9, 2025 | Wong JeromeChief Financial Officer | Sale | 1,238 | $4.70 | $5.8K | Form 4 |
| Nov 10, 2025 | Wong JeromeChief Financial Officer | Sale | 11,288 | $4.80 | $54.2K | Form 4 |
| Nov 10, 2025 | Jones Jason CChief Operating Officer | Sale | 9,723 | $4.80 | $46.7K | Form 4 |
| Nov 10, 2025 | Davis Scott G.Director | Sale | 23,315 | $4.80 | $111.9K | Form 4 |
| Nov 2, 2023 | Lathan CorinnaDirector | Buy | 4,032 | $1.24 | $5.0K | Form 4 |
| Aug 23, 2023 | Lathan CorinnaDirector | Buy | 5,500 | $0.95 | $5.2K | Form 4 |
| Aug 17, 2023 | Davis Scott G.Director | Sale | 37,446 | $1.00 | $37.4K | Form 4 |
| Aug 17, 2023 | Wong JeromeChief Financial Officer | Sale | 12,784 | $1.00 | $12.8K | Form 4 |
All 44 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Applied Digital Corp.SCHEDULE 13D/A, 2 filings May 12, 2026 to Jun 26, 202667
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 6 filings Nov 14, 2024 to May 15, 202668
- Mink Brook Asset Management LLCSCHEDULE 13G/A, 2 filings Apr 9, 2026 to May 14, 202669
- Keith KosowSCHEDULE 13G, 1 filing Mar 19, 202670
- Daniel AsherSCHEDULE 13G/A, 2 filings Jan 8, 2026 to Jan 29, 202671
- Kent Lake PR LLCSCHEDULE 13G/A, 2 filings Sep 12, 2024 to Feb 14, 202572
- Azimut Investments S.A.SC 13G/A, 1 filing Feb 11, 202273
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 44. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How ChronoScale Holdings Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARChronoScale Holdings Corp1
- CIK0001549084
- Employer ID (EIN)42-33570055
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inNevada5
- Fiscal year endsMay 311
- Industry code (SIC)3569 General Industrial Machinery & Equipment, NEC1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address2440 Sand Hill Road, Suite 400, Menlo Park, CA 940251
- Phone(650) 977-49691
- Shares outstanding145,637,452 as of Oct 13, 202614
- Public float$15.6M as of Nov 28, 20255
- AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceMay 8, 20121
- Filings725 in all: 4 (183), 8-K (168), 10-Q (44), 3 (38), UPLOAD (21), S-8 (20), 424B3 (18), 424B5 (18)1
All 55 form types
CORRESP (17), 10-K (14), DEF 14A (14), EFFECT (14), 8-K/A (11), S-8 POS (11), 10-Q/A (10), DEFA14A (10), 4/A (9), S-1/A (8), S-3 (8), SCHEDULE 13G/A (8), D (6), SC 13D/A (6), 11-K (5), PRE 14A (5), SC 13G (5), ARS (4), S-1 (4), SCHEDULE 13G (4), 10-K/A (3), 424B1 (3), FWP (3), NT 10-Q (3), SC TO-I/A (3), 3/A (2), POS AM (2), PRER14C (2), SC 13D (2), SEC STAFF LETTER (2), 424B2 (1), 424B4 (1), 8-A12B (1), 8-A12G (1), 8-K12B (1), CERTNAS (1), CT ORDER (1), DEF 14C (1), DRS (1), NTN 10K (1), PREM14C (1), PRER14A (1), S-3/A (1), SC 13G/A (1), SC TO-I (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Aug 19, 2026
Quarterly report (10-Q) Oct 14, 2026
Proxy statement (DEF 14A) Sep 25, 2026
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | CHRN | Nasdaq |
From the cover page of the 10-K filed Aug 19, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks ChronoScale Holdings Corp names in Item 1A of its 10-K filed Aug 19, 2026: 61 risks under these headings, as written.5
- ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and financial condition. If any of the following risks actually materialize, our business, financial condition and/or operations could suffer. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money that you paid for our common stock.
- Risks Related to Our Business and Operations
- Combining our Legacy Ekso Business and Cloud Business may be more difficult, costly and time-consuming than expected, which may adversely affect our results and negatively affect the value of our common stock.
- We expect to need to raise external funds to support our growth strategy. Such capital raises are expected to cause dilution to our stockholders.
- We are a “controlled company” under Nasdaq’s corporate governance rules and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. As a result, investors in the Company do not have the same protections afforded to stockholders of companies that are subject to such requirements.
- Commencing November 30, 2026 (the end of our second fiscal quarter), we will no longer qualify as a smaller reporting company and will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results.
- We have a history of net losses and may continue to incur net losses for the foreseeable future.
- Our Cloud Business has had, and is expected to continue to have, significant customer concentration.
- Failure to attract, grow and retain a diverse and balanced customer base, including key magnet customers, could harm our business and operating results.
- Our Cloud Business’ customer has historically made advance deposits based on anticipated future usage, and may continue to do so.
- We may face pricing pressures as our industry evolves, and any significant or sustained reductions in pricing may reduce our margins and adversely affect our business, operating results, financial condition and future prospects.
- Technological developments in generative AI and inference, such as the development of AI models that require less computation power than earlier models, may result in decreased or differing demand for our offerings.
The other 50 risks
- Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, which could result in our business failing to meet its growth targets, which could negatively affect our financial condition, results of operations and future prospects.
- Our Cloud Business faces significant and evolving competition, and any inability to adapt to new and changing technologies and customer requirements or specifications could negatively affect our financial condition, results of operations and future prospects.
- We are currently dependent on a limited number of suppliers and our Cloud Business may be adversely affected if we are unable to source and acquire sophisticated hardware on acceptable terms and on time. Any supply chain disruptions, delays in delivery or increased costs could adversely affect our growth plans, financial condition and results of operations.
- Any disruption to colocation space or services from third-party providers, or our ineffective management of relationships with third parties could harm our business, financial condition, operating results, cash flows, and prospects.
- Cybersecurity, physical security, and infrastructure disruptions could materially adversely affect our business.
- Certain natural disasters or other external events, including climate change or mechanical failures, could harm our business, financial condition, results of operations, cash flows, and prospects.
- We may be unable to deploy GPU infrastructure on the timelines committed to Microsoft, or at all, and any such delays in deployment or failure to deploy could result in significant financial penalties against us, contract termination, or loss of some or substantially all of our anticipated revenue.
- As we invest in our expansion efforts, if we fail to effectively manage our growth, our business, financial condition and results of operations could be harmed.
- Our level of debt in the future may negatively impact our liquidity, restrict our operations and ability to respond to business opportunities, and increase our vulnerability to adverse economic and industry conditions.
- Joint ventures, joint ownership arrangements and other projects pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated benefits associated with such projects.
- The loss of any of our management team, our inability to execute an effective succession plan, or our inability to attract and retain qualified personnel, could adversely affect our business.
- We may become involved in litigation arising in the ordinary course of our business that may materially adversely affect us.
- Employee disputes or litigation and related unfavorable publicity may negatively affect our future business, financial condition, and operating results.
- Unfavorable global economic conditions and adverse developments with respect to financial institutions and associated liquidity risk could adversely affect our business, financial condition and stock price.
- The development and use of AI tools is subject to intense political scrutiny and evolving, complex and potentially divergent regulatory frameworks across multiple jurisdictions, and the impact of such regulatory developments on our businesses remains uncertain. If we are unable to comply with such laws and regulations and related export controls and other regulations, or if such requirements limit our ability to implement our business model, we may be subject to litigation, investigation or penalties, and our businesses and results of operations could be negatively impacted.
- Our inability to market and close the sale of our Legacy Ekso Business that is currently held for sale and treated as discontinued operations may have a material adverse impact on our business and financial condition.
- Risks Related to Our Common Stock
- Our stock price may be subject to volatility; this volatility may affect your ability to, and the price at which you could, sell our common stock.
- Future issuances of our equity securities may result in dilution to existing stockholders and could adversely affect the market price of our common stock.
- We do not expect to declare or pay dividends in the foreseeable future, which may limit the return our shareholders realize on their investment.
- Provisions in our Articles (as defined below), our Bylaws (as defined below), and Nevada law may discourage a takeover attempt even if a takeover might be beneficial to our stockholders.
- We are currently a “smaller reporting company” and the reduced reporting requirements applicable to such companies may make our common stock less attractive to investors.
- Risks Related to our Legacy Ekso Business
- If we fail to manage the complex and lengthy reimbursement process, our Legacy Ekso Business and operating results could be adversely affected.
- The markets in which our products are sold are highly competitive and continue to develop, and important assumptions about the potential market for our current and future products may be inaccurate.
- If we or our third-party manufacturers are unable to produce our products at a satisfactory quality, in a timely manner, in sufficient quantities or at an acceptable cost, our Legacy Ekso Business could be negatively impacted.
- Shortages in the materials used to manufacture our products and supply chain disruptions, including as a result of changes in trade policies, could impact our current operations.
- Certain of our Legacy Ekso Business customers utilize federal funding to purchase our products, and recent federal policy changes have disrupted, and could continue to disrupt, that funding.
- Coverage policies and reimbursement levels of third-party payors, including VA, Medicare, Medicaid, and commercial payors may affect current demands for Legacy Ekso products.
- We will experience long and variable sales cycles.
- International sales of current Legacy Ekso products are subject to factors outside of our control.
- We have historically relied, and in the future may rely, on sales of our EksoNR, Ekso Indego Therapy and Ekso Indego Personal for a significant portion of our Legacy Ekso Business revenue.
- We rely on independent distributors for the sale and marketing of our products in certain geographies.
- Shutdowns of the U.S. federal government could materially impair our Legacy Ekso Business and financial condition.
- Legacy Ekso Intellectual Property Risks
- Protecting our intellectual proprietary rights can be costly, and our success in doing so is not certain.
- Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
- Some Legacy Ekso patents and patent applications are not within our complete control, which could reduce the value of those assets.
- If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third-parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.
- Patent terms may be inadequate to protect our competitive position on our devices for an adequate amount of time.
- Legacy Ekso Legal and Regulatory Compliance Risks
- If we fail to obtain or maintain necessary regulatory clearances or approvals for our Legacy Ekso medical device products, our Legacy Ekso Business could be harmed.
- Our Legacy Ekso products and operations are subject to extensive government regulation and oversight in the United States and other countries where we commercialize our medical devices.
- Modifications to our current and future Legacy Ekso products may require new 510(k) clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
- We must obtain certain regulatory approvals in the EU, which could be costly and time-consuming and subject us to unanticipated delays or prevent us from marketing certain devices.
- Our failure to meet strict post-market regulatory requirements with respect to our products could require us to pay fines, incur other costs or even close our facilities.
- We may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or “off-label” uses.
- We may be subject to adverse medical device reporting obligations, voluntary corrective actions or agency enforcement actions.
- Failure to comply with anti-kickback and fraud regulations could result in substantial penalties and changes in our business operations.
- Changes in law or regulation could make it more difficult and costly for us to manufacture, market and distribute our products or obtain or maintain regulatory approval of new or modified products.
- Failure to comply with Health Insurance Portability and Accountability Act (HIPAA) or the HITECH Act and implementing regulations could result in significant penalties.
- Legacy Ekso Product Liability Risks
- Our Legacy Ekso products may become subject to voluntary or involuntary recall.
- Our product liability insurance may not adequately cover potential claims or recalls.
- Warranty claims and maintenance obligations for current Legacy Ekso products could result in additional operating costs.
Legal proceedings
From time to time, we may become involved in legal proceedings and claims arising in the ordinary course of business.
As of May 31, 2026, there were no pending or threatened lawsuits that could reasonably be expected to have a material adverse effect on the results of the Company’s consolidated operations. There are also no legal proceedings in which any of the Company's management or affiliates is an adverse party or has a material interest adverse to the Company's interest.
The results of any litigation cannot be predicted with certainty, and an unfavorable resolution in any legal proceedings could materially affect our future business, results of operations, or financial condition. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. For additional information, please refer to Note 16. Commitments and Contingencies in our notes to the consolidated financial statements.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARTom Looby, Chief executive officer
- 18
- 19SEC EDGARJack Peurach, President
- 20SEC EDGARRuss Angold, President
- 21SEC EDGARTom Looby, President
- 22SEC EDGARJohn Glenn, Chief financial officer
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARDouglas S. Miller, Board member
- 30SEC EDGARElla Gendel, Board member
- 31SEC EDGARRichard N. Nottenburg, Board member
- 32SEC EDGARWes Cummins, Board member
- 33SEC EDGARWilliam M. Clancy, Board member
- 34SEC EDGARAndrew Cordell Schaap, Board member
- 35SEC EDGARDeborah Lafer Scher, Board member
- 36SEC EDGARMary Ann Cloyd, Board member
- 37SEC EDGARCorinna Lathan, Board member
- 38SEC EDGARRhonda A. Wallen, Board member
- 39SEC EDGARKecheng Li, Board member
- 40SEC EDGARThomas A. Schreck, Board member
- 41SEC EDGARHoward D. Palefsky, Board member
- 42SEC EDGARTheodore T. Wang, Board member
- 43SEC EDGARTom Looby, Board member
- 44SEC EDGARAmy McBride Wendell, Board member
- 45SEC EDGARDaniel Boren, Board member
- 46SEC EDGARJack Peurach, Board member
- 47SEC EDGARMarilyn Hamilton, Board member
- 48SEC EDGARStanley Stern, Board member
- 49SEC EDGARResults of operations
- 50SEC EDGARExecutive or director change
- 51
- 52SEC EDGAREntered a material agreement
- 53
- 54SEC EDGARExecutive or director change
- 55
- 56SEC EDGAROther events
- 57
- 58SEC EDGARExit or restructuring costs
- 59SEC EDGARExecutive or director change
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73